54th ESPGHAN
Noventure will be present at the 54th ESPGHAN, that will take place in Copenhaguen, Denmark 22-25 June 2022
TASECTAN® DUO
0
Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018
As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018.
Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information.
Our innovative products intended for acute diarrhea (TASECTAN®, TASECTAN DUO® and XILAPLUS®) attracted a lot of interest from doctors.
New Scientific publication on TASECTAN® DUO
Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct 25.
Pathogenic microorganisms can adhere to the intestinal mucosa and influence cellular tight-junction function, leading to diarrhea. In an in vitro study, it was compared the protective efficacy of a combination of gelatine tannate plus inactivated probiotic (Tasectan® Duo) with that of other widely used antidiarrheal agents (Diosmectite, Saccharomyces boulardii, and a probiotic mixture).
The study results clearly show that the protective efficacy of Tasectan® Duo manifests early and is maintained for 24 h. This effect is quicker and lasts longer that with the other compounds evaluated. These data further reinforce the potential broad utility of Tasectan® Duo in the management of diarrhea of several causes (e.g., infectious gastroenteritis, antibiotic therapy and chemotherapy) in population groups of all ages.
Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct 25. doi: 10.2217/fmb-2016-0195.
